Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Management and Research"
DOI: 10.2147/cmar.s372125
Abstract: Objective Lenvatinib was the standard first-line therapy for patients with unresectable HCC. PD-1 blockades demonstrated promising efficacy for patients with previously-treated HCC. Therefore, this study was to investigate the feasibility and tolerability of lenvatinib plus… read more here.
Keywords: patients unresectable; plus blockades; lenvatinib plus; response ... See more keywords